Phase 2 Trial for Plague Vaccine Begins
Global Security Newswire
DynPort Vaccine Co. has begun the second phase of its clinical trial on a recombinant plague vaccine, the company said last month (see GSN, Dec. 20).
The trial, which is expected to test varying dosages and schedules in 400 healthy adult volunteers, is scheduled to continue into next year at eight U.S. locations.
“An effective, licensed plague vaccine is a crucial component of U.S. biodefense initiatives,” Robert House, DynPort’s president and chief scientific officer, said in a press release. “Plague has been identified as a Category A bioterrorism agent by the Centers for Disease Control and Prevention. The candidate’s entry into a phase 2 trial is a significant step toward DVC’s goal of a licensed plague vaccine” (DynPort Vaccine Co. release, July 12).
DynPort Vaccine Co. has begun the second phase of its clinical trial on a recombinant plague vaccine, the company said last month (see GSN, Dec. 20).
The trial, which is expected to test varying dosages and schedules in 400 healthy adult volunteers, is scheduled to continue into next year at eight U.S. locations.
“An effective, licensed plague vaccine is a crucial component of U.S. biodefense initiatives,” Robert House, DynPort’s president and chief scientific officer, said in a press release. “Plague has been identified as a Category A bioterrorism agent by the Centers for Disease Control and Prevention. The candidate’s entry into a phase 2 trial is a significant step toward DVC’s goal of a licensed plague vaccine” (DynPort Vaccine Co. release, July 12).
